DNTH vs. RNA, MLTX, TGTX, ACAD, ARVN, INDV, SMMT, JANX, BHC, and RYTM
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Avidity Biosciences (RNA), MoonLake Immunotherapeutics (MLTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Indivior (INDV), Summit Therapeutics (SMMT), Janux Therapeutics (JANX), Bausch Health Companies (BHC), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences (NASDAQ:RNA) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Avidity Biosciences has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Dianthus Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avidity Biosciences had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Avidity Biosciences and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.03 beat Avidity Biosciences' score of 0.63 indicating that Avidity Biosciences is being referred to more favorably in the media.
Avidity Biosciences presently has a consensus price target of $41.33, suggesting a potential upside of 53.88%. Dianthus Therapeutics has a consensus price target of $42.83, suggesting a potential upside of 98.21%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Avidity Biosciences.
47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.7% of Avidity Biosciences shares are owned by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Avidity Biosciences received 126 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Dianthus Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,103.78%. Avidity Biosciences' return on equity of -20.82% beat Dianthus Therapeutics' return on equity.
Summary
Dianthus Therapeutics beats Avidity Biosciences on 10 of the 16 factors compared between the two stocks.
Get Dianthus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
